Literature DB >> 22743673

Objective measurement of cough in otherwise healthy volunteers with acute cough.

Kanchan Sunger1, William Powley, Angela Kelsall, Helen Sumner, Robert Murdoch, Jaclyn A Smith.   

Abstract

Cough is one of the commonest reasons for medical consultation and acute cough associated with upper respiratory tract infections (URTIs) is a global problem. In otherwise healthy volunteers complaining of cough associated with symptoms of URTI, we aimed to assess objective and subjective measures of cough and their repeatability and perform power calculations for the design of future studies to test therapies. We studied 54 otherwise healthy volunteers with acute cough (<3 weeks) (median age 22 yrs (interquartile range 21-26 yrs), 64% female, mean forced expiratory volume in 1 s 97.6±10.5% predicted). All subjects performed 24-h ambulatory cough monitoring and reported cough frequency and severity using visual analogue scales (VAS) on 2 consecutive days. Sample size calculations were performed for crossover and parallel group study designs. Objective cough frequency was high (session 1: geometric mean 12.1 coughs·h(-1) (95%CI 9.7-15.2)) and fell significantly (session 2: 9.0 coughs·h(-1) (95%CI 6.9-11.6); p<0.001). Repeatability was higher for objective cough frequency (intra-class correlation coefficient (ICC)=0.94, p<0.001) than reported cough frequency (daytime VAS ICC=0.784, p<0.001). Crossover/parallel studies require <15 and <41 subjects per arm to detect a 50% reduction in cough frequency with 90% power, respectively. Acute cough frequency is highly repeatable over any 48-h period, allowing small sample sizes to be used when investigating the effectiveness of novel anti-tussives.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22743673     DOI: 10.1183/09031936.00190111

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  4 in total

Review 1.  An update on measurement and monitoring of cough: what are the important study endpoints?

Authors:  Arietta Spinou; Surinder S Birring
Journal:  J Thorac Dis       Date:  2014-10       Impact factor: 2.895

2.  Tools for assessing outcomes in studies of chronic cough: CHEST guideline and expert panel report.

Authors:  Louis-Philippe Boulet; Remy R Coeytaux; Douglas C McCrory; Cynthia T French; Anne B Chang; Surinder S Birring; Jaclyn Smith; Rebecca L Diekemper; Bruce Rubin; Richard S Irwin
Journal:  Chest       Date:  2015-03       Impact factor: 9.410

Review 3.  The present and future of cough counting tools.

Authors:  Jocelin Isabel Hall; Manuel Lozano; Luis Estrada-Petrocelli; Surinder Birring; Richard Turner
Journal:  J Thorac Dis       Date:  2020-09       Impact factor: 3.005

4.  Treatment with the P2X3-Receptor Antagonist Gefapixant for Acute Cough in Induced Viral Upper Respiratory Tract Infection: A Phase 2a, Randomized, Placebo-Controlled Trial.

Authors:  Jaclyn A Smith; Michael M Kitt; Alan Bell; Nicolas Noulin; Anjela Tzontcheva; Megan McGratty Seng; Susan Lu
Journal:  Pulm Ther       Date:  2022-08-15
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.